Yunpeng Liu

机构：Capital Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Normal University, Jilin Province Tumor Hospital, Kyungil University, Yunnan Machinery Research and Design Institute, Model Animal Research Center, Institute of Laboratory Animal Science, National Institute of Animal Health · ORCID：0000-0001-9800-4373

发表论文 324 篇 · 总被引 9478 次 · h-index 49

代表论文

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 516)
• The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update (2024 · 癌症：英文版 · 被引 70)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 28)
• A multilayer perceptron-based model applied to histopathology image classification of lung adenocarcinoma subtypes (2023 · Frontiers in Oncology · 被引 17)
• Intestinal Gastrin/CCKBR Axis Protects against Type 2 Diabetes by Reducing Intestinal Glucose Absorption through the PI3K/Akt/eIF4B Signaling Pathway (2025 · Advanced Science · 被引 7)
• Analysis of the aging-related biomarker in a nonhuman primate model using multilayer omics (2024 · BMC Genomics · 被引 7)